{"id":130780,"date":"2026-06-25T12:00:41","date_gmt":"2026-06-25T06:30:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=130780"},"modified":"2026-06-25T12:00:42","modified_gmt":"2026-06-25T06:30:42","slug":"avience-biomedicals-ipo-listing-price-gain-subscription-385x","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/avience-biomedicals-ipo-listing-price-gain-subscription-385x\/","title":{"rendered":"Avience Biomedicals IPO Listing: Opens at Rs 395 (+90%), Surges to Rs 415, 385x Subscription Delivers Spectacular NSE SME Debut"},"content":{"rendered":"
<\/div>\n

Avience Biomedicals IPO listing: open Rs 395.20 (+90%), LTP Rs 414.95 (+99.5%), issue price Rs 208. Subscription 385.32x. Retail 401x, NII 597x. Issue size Rs 30.24 Cr. NSE SME. IVD diagnostics.<\/em><\/p>\n

The Avience Biomedicals<\/a> IPO has delivered one of the most spectacular SME listings seen this month. Shares of Avience Biomedicals opened on NSE SME at Rs 395.20 today, a premium of approximately 90% over the IPO price of Rs 208, and have since extended gains to Rs 414.95, representing a listing-day return of approximately 99.5% for allottees. Ankit Jaiswal, Senior Research Analyst at Univest notes that the Avience Biomedicals IPO listing performance is exceptional even by the standards of the currently buoyant SME IPO market , the 385x overall subscription was a clear signal that institutional and retail demand was extremely strong, but the actual listing has blown past even the most optimistic GMP estimates of Rs 266-278 (approximately 28-33% premium) that were circulating during the subscription period.<\/p>\n

The Avience Biomedicals IPO was subscribed 385.32 times on the final day of bidding. Breaking this down by investor category: retail individual investors subscribed 401.36 times, Non-Institutional Investors (NII\/HNI) subscribed 597.23 times, and Qualified Institutional Buyers subscribed 196.77 times. All three categories showed exceptional demand, with the NII oversubscription of 597x being particularly notable as it reflects serious institutional and HNI conviction in the Avience Biomedicals IPO thesis. The grey market had been pricing a GMP of Rs 58-70 in the week leading up to listing, implying an expected listing price of Rs 266-278 , approximately 28-33% above issue price. The actual opening of Rs 395.20 (+90%) nearly tripled that GMP estimate, demonstrating how even strong GMP signals can underestimate the market’s appetite for high-conviction SME issues.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n